Impact of treatment decision algorithms on treatment costs in recurrent glioblastoma: a health economic study

AIMS Recurrent glioblastoma (GBM) is a disease with poor prognosis. Although several therapeutic approaches such as chemotherapy, irradiation or surgery have been investigated, there is no established standard therapy. A recent survey among Swiss neuro-oncology centres has shown considerable controv...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Swiss medical weekly Ročník 149; číslo 4950; s. w20153
Hlavní autoři:	Panje, Cédric M., Putora, Paul M., Hundsberger, Thomas, Hottinger, Andreas F., Roelcke, Ulrich, Pesce, Gianfranco, Herrmann, Evelyn, Matter-Walstra, Klazien
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Switzerland SMW supporting association (Trägerverein Swiss Medical Weekly SMW) 02.12.2019
Témata:	Adult Algorithms Bevacizumab - therapeutic use Chronic Disease Clinical Decision-Making Female glioblastoma Glioblastoma - drug therapy Health Care Costs - statistics & numerical data Humans Male Medical Oncology Middle Aged Neoplasm Recurrence, Local - drug therapy oncology Switzerland Temozolomide - therapeutic use treatment algorithm Switzerland
ISSN:	1424-3997, 1424-3997
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!